# Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

> **NCT02521714** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 28 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02521714
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-14
- **Primary completion:** 2015-09-23
- **Final completion:** 2015-09-23
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521714, "Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02521714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*